Bucheon, South Korea · Founded 2017 · Privately Held (backing)
Operator of a biomedical company intended to make botulinum toxin. Inibio is based in Bucheon, South Korea and was founded in 2017. Its last reported valuation was $129 million in Feb 2025.
Last reported valuation
$129.2M
Oct 2026
Priced at
—
Total raised
—
Last round
—
Team — not yet on record
No current team members for Inibio are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Inibio with a free account
·Watch Inibio: the Monday email on marks, rounds and moves
